Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free MBOT Stock Alerts

Microbot Medical (MBOT) Competitors

Microbot Medical logo
$1.48 -0.02 (-1.33%)
As of 08/28/2026 04:00 PM Eastern
Compare

MBOT vs. MOBI, ELMD, TLSI, OBIO, and RCEL

Should you buy Microbot Medical stock or one of its competitors? Microbot Medical's main competitors and comparable companies include Mobia Medical (MOBI), Electromed (ELMD), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), and Avita Medical (RCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Microbot Medical compare to Mobia Medical?

Microbot Medical (NASDAQ:MBOT) and Mobia Medical (NASDAQ:MOBI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Mobia Medical's return on equity of 0.00% beat Microbot Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -21.87% -20.76%
Mobia Medical N/A N/A N/A

16.3% of Microbot Medical shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Microbot Medical presently has a consensus price target of $6.38, indicating a potential upside of 330.74%. Mobia Medical has a consensus price target of $20.75, indicating a potential upside of 82.98%. Given Microbot Medical's higher possible upside, equities research analysts clearly believe Microbot Medical is more favorable than Mobia Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Mobia Medical
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Microbot Medical has higher earnings, but lower revenue than Mobia Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot MedicalN/AN/A-$13.14M-$0.24N/A
Mobia Medical$45.28M8.34-$46.50M-$20.18N/A

In the previous week, Mobia Medical had 1 more articles in the media than Microbot Medical. MarketBeat recorded 3 mentions for Mobia Medical and 2 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.74 beat Mobia Medical's score of 0.62 indicating that Microbot Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Microbot Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mobia Medical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Mobia Medical beats Microbot Medical on 7 of the 13 factors compared between the two stocks.

How does Microbot Medical compare to Electromed?

Electromed (NYSE:ELMD) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Electromed has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Electromed$73.78M3.32$5.15M$1.3122.60
Microbot MedicalN/AN/A-$13.14M-$0.24N/A

Electromed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

In the previous week, Electromed had 7 more articles in the media than Microbot Medical. MarketBeat recorded 9 mentions for Electromed and 2 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.74 beat Electromed's score of 0.50 indicating that Microbot Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Electromed
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Microbot Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Electromed currently has a consensus price target of $43.75, indicating a potential upside of 47.80%. Microbot Medical has a consensus price target of $6.38, indicating a potential upside of 330.74%. Given Microbot Medical's higher possible upside, analysts clearly believe Microbot Medical is more favorable than Electromed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

40.8% of Electromed shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Electromed has a net margin of 11.34% compared to Microbot Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Microbot Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Electromed11.34% 15.71% 13.37%
Microbot Medical N/A -21.87%-20.76%

Summary

Electromed beats Microbot Medical on 11 of the 14 factors compared between the two stocks.

How does Microbot Medical compare to TriSalus Life Sciences?

Microbot Medical (NASDAQ:MBOT) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Microbot Medical has higher earnings, but lower revenue than TriSalus Life Sciences. Microbot Medical is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot MedicalN/AN/A-$13.14M-$0.24N/A
TriSalus Life Sciences$45.15M6.59-$39.23M-$1.30N/A

Microbot Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Microbot Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -21.87% -20.76%
TriSalus Life Sciences -62.59%N/A -64.47%

In the previous week, Microbot Medical and Microbot Medical both had 2 articles in the media. TriSalus Life Sciences' average media sentiment score of 1.01 beat Microbot Medical's score of 0.74 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Microbot Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TriSalus Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Microbot Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Microbot Medical currently has a consensus price target of $6.38, indicating a potential upside of 330.74%. TriSalus Life Sciences has a consensus price target of $7.50, indicating a potential upside of 55.28%. Given Microbot Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Microbot Medical is more favorable than TriSalus Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Microbot Medical beats TriSalus Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Microbot Medical compare to Orchestra BioMed?

Microbot Medical (NASDAQ:MBOT) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Microbot Medical presently has a consensus price target of $6.38, indicating a potential upside of 330.74%. Orchestra BioMed has a consensus price target of $13.00, indicating a potential upside of 150.97%. Given Microbot Medical's higher probable upside, research analysts clearly believe Microbot Medical is more favorable than Orchestra BioMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Orchestra BioMed
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Microbot Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -184.60%. Microbot Medical's return on equity of -21.87% beat Orchestra BioMed's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -21.87% -20.76%
Orchestra BioMed -184.60%-149.61%-54.15%

Microbot Medical has higher earnings, but lower revenue than Orchestra BioMed. Microbot Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot MedicalN/AN/A-$13.14M-$0.24N/A
Orchestra BioMed$31.98M9.74-$52.70M-$0.85N/A

Microbot Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Orchestra BioMed had 4 more articles in the media than Microbot Medical. MarketBeat recorded 6 mentions for Orchestra BioMed and 2 mentions for Microbot Medical. Orchestra BioMed's average media sentiment score of 1.29 beat Microbot Medical's score of 0.74 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Microbot Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Orchestra BioMed
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Orchestra BioMed beats Microbot Medical on 8 of the 15 factors compared between the two stocks.

How does Microbot Medical compare to Avita Medical?

Microbot Medical (NASDAQ:MBOT) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Microbot Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Avita Medical has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

Microbot Medical has a net margin of 0.00% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat Microbot Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -21.87% -20.76%
Avita Medical -56.96%N/A -78.53%

In the previous week, Microbot Medical and Microbot Medical both had 2 articles in the media. Avita Medical's average media sentiment score of 1.48 beat Microbot Medical's score of 0.74 indicating that Avita Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Microbot Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avita Medical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Microbot Medical has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot MedicalN/AN/A-$13.14M-$0.24N/A
Avita Medical$75.63M4.21-$48.59M-$1.44N/A

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Microbot Medical presently has a consensus price target of $6.38, indicating a potential upside of 330.74%. Avita Medical has a consensus price target of $11.40, indicating a potential upside of 10.14%. Given Microbot Medical's higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than Avita Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Avita Medical
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Microbot Medical and Avita Medical tied by winning 7 of the 14 factors compared between the two stocks.

Get Microbot Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBOT vs. The Competition

Export
MetricMicrobot MedicalHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$99.40M$5.82B$7.20B$12.90B
Dividend YieldN/A1.75%2.54%11.28%
P/E Ratio-6.1725.92273.1625.45
Price / SalesN/A67.77640.1989.89
Price / CashN/A33.0376.7453.00
Price / Book1.446.1812.986.14
Net Income-$13.14M$149.01M$3.48B$348.86M
7 Day Performance-1.33%-0.24%0.13%-0.80%
1 Month Performance-14.94%6.18%7.08%4.13%
1 Year Performance-61.15%6.30%24.67%15.17%

Microbot Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBOT
Microbot Medical
2.1197 of 5 stars		$1.48
-1.3%		$6.38
+330.7%		-61.2%$99.40MN/AN/A20
MOBI
Mobia Medical
4.3146 of 5 stars		$10.98
+3.5%		$20.75
+89.0%		N/A$353.22M$32.04MN/AN/A
ELMD
Electromed
3.1536 of 5 stars		$40.29
+2.1%		$37.50
-6.9%		+19.7%$333.60M$71.75M53.72160
TLSI
TriSalus Life Sciences
1.2327 of 5 stars		$5.11
-3.0%		$7.50
+46.8%		-7.5%$324.50M$45.08MN/A106
OBIO
Orchestra BioMed
3.6928 of 5 stars		$5.44
+1.5%		$13.00
+139.0%		+89.7%$322.16M$33.48MN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MBOT) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
A Worldwide Gold Lockdown Is Now Underway
Gold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...
Stansberry Research | Sponsoredtc pixel
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel